SCHEMBL6022720

SCHEMBL6022720

CCCC(C)Oc1cc(C=CC(=O)Nc2ccccc2)cc(OC(C)CCC)c1O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 1/20 0.54
MEN1 O00255 1/20 0.53
NPC1 O15118 1/20 0.53
STAT1 P42224 1/20 0.53
RAB9A P51151 1/20 0.53
KMT2A Q03164 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
MMP1 P03956 6/20 0.51
MMP2 P08253 6/20 0.51
MMP9 P14780 6/20 0.51
TOP2A P11388 1/20 0.49
EGFR P00533 3/20 0.49
MAOA P21397 1/20 0.49
MAOB P27338 1/20 0.49
BCHE P06276 5/20 0.47
ACHE P22303 5/20 0.47
ALOX5 P09917 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.45
DEGS1 O15121 1/20 0.45
METAP2 P50579 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6022715 1.00 KDM1A (0.54) KDM1AMEN1NPC1STAT1RAB9A
SCHEMBL6023301 0.87 KDM1A (0.56) KDM1AMEN1NPC1RAB9AKMT2A
SCHEMBL6023294 0.87 KDM1A (0.56) KDM1AMEN1NPC1RAB9AKMT2A
SCHEMBL6023357 0.85 KDM1A (0.57) KDM1AMEN1NPC1STAT1RAB9A
SCHEMBL6023356 0.85 KDM1A (0.57) KDM1AMEN1NPC1STAT1RAB9A
SCHEMBL6023707 0.79 BCHE (0.60) KDM1ABCHEACHE
SCHEMBL6023711 0.79 BCHE (0.60) KDM1ABCHEACHE
SCHEMBL6022945 0.76 MMP1 (0.62) KDM1AMEN1NPC1RAB9AKMT2A
SCHEMBL6022941 0.76 MMP1 (0.62) KDM1AMEN1NPC1RAB9AKMT2A
SCHEMBL6022585 0.74 ALOX5 (0.40) KMT2AMMP1MMP2MMP9MAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030162789-A1 4-Hydroxycinnamamide derivatives as antioxidants and pharmaceutical compositions containing them KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2003-08-28 US claimed
US-7078407-B2 4-hydroxycinnamamide derivatives as antioxidants and pharmaceutical compositions containing them KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2006-07-18 US disclosed
US-20030162789-A1 4-Hydroxycinnamamide derivatives as antioxidants and pharmaceutical compositions containing them KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2003-08-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030162789-A1 4-Hydroxycinnamamide derivatives as antioxidants and pharmaceutical compositions containing them HTT, PARK7, NQO1 KDM1A 2590/4885MEN1 3297/4885NPC1 568/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.